Clinigen Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
1,100
- Latest Deal Type
-
Debt - Acquisition
- Financing Rounds
-
7
- Investments
-
18
Clinigen General Information
Description
Manufacturer of pharmaceutical products and services intended to offer quicker access to new and critical medicines. The company operates in a range of areas of global medicine supply including clinical trials, unlicensed medicines and licensed medicines, enabling clients to deliver the right medicine to the right patient at the right time.
Contact Information
Website
www.clinigengroup.comCorporate Office
- Pitcairn House
- Crown Square, First Avenue
- Burton upon Trent DE14 2WW
- England, United Kingdom
Corporate Office
- Pitcairn House
- Crown Square, First Avenue
- Burton upon Trent DE14 2WW
- England, United Kingdom
Clinigen Timeline
Clinigen Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Clinigen Comparisons
Industry
Financing
Details
Clinigen Competitors (2)
One of Clinigen’s 2 competitors is Advanz Pharma, a Private Equity-Backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Advanz Pharma | Private Equity-Backed | London, United Kingdom | ||||
| Almac Group | Venture Capital-Backed | Craigavon, United Kingdom |
Clinigen Patents
Clinigen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2016051213-A1 | Par inhibition | Inactive | 17-Dec-2014 | ||
| CA-2596422-C | 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy | Inactive | 08-Feb-2005 | ||
| US-20170145046-A1 | 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy | Inactive | 08-Feb-2005 | ||
| US-20190085017-A1 | 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy | Inactive | 08-Feb-2005 | ||
| CA-2557857-A1 | Cancer treatment with topoisomerase-ii inhibitor, a bis-dioxypiperazine and radiation | Active | 02-Mar-2004 | A61K31/496 |
Clinigen Signals
Clinigen Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Clinigen Investments & Acquisitions (18)
Clinigen’s most recent deal was a Buyout/LBO with SSI Strategy. The deal was made on 04-Nov-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| SSI Strategy | 04-Nov-2025 | Buyout/LBO | Consulting Services (B2B) | ||
| Kinesys Consulting | 31-Jul-2024 | Buyout/LBO | Consulting Services (B2B) | ||
| Ascenian | 31-May-2024 | Buyout/LBO | Consulting Services (B2B) | ||
| Drug Safety Navigator | 29-Nov-2022 | Buyout/LBO | Practice Management (Healthcare) | ||
| iQone | 09-Oct-2018 | Merger/Acquisition | Pharmaceuticals |
Clinigen Exits (4)
Clinigen’s most recent exit was on 09-Oct-2018 from iQone. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| iQone | 09-Oct-2018 | Completed |
|
||
| Proleukin | 02-Apr-2018 | Completed |
|
||
| Quantum Pharma Holdings | 01-Nov-2017 | Completed |
|
||
| Theravance (Commercialization rights to VIBATIV) | 11-Mar-2013 | Corporate Asset Purchase | Completed |
Clinigen Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Link Healthcare | Warriewood, Australia | 1997 |
Clinigen FAQs
-
When was Clinigen founded?
Clinigen was founded in 2008.
-
Where is Clinigen headquartered?
Clinigen is headquartered in Burton upon Trent, United Kingdom.
-
What is the size of Clinigen?
Clinigen has 1,100 total employees.
-
What industry is Clinigen in?
Clinigen’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Clinigen a private or public company?
Clinigen is a Private company.
-
What is Clinigen’s current revenue?
The current revenue for Clinigen is .
-
How much funding has Clinigen raised over time?
Clinigen has raised $293M.
-
Who are Clinigen’s investors?
Triton Partners has invested in Clinigen.
-
Who are Clinigen’s competitors?
Advanz Pharma and Almac Group are competitors of Clinigen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process